Article Figures & Data
Figures
- Fig 1.
The factors influencing the suitability of a radionuclide for use in radiation therapy.
- Fig 2.
After defining the therapeutic need, the provider should use a well-organized collection of information that determines radionuclide suitability by evaluating numerous isotopic characteristics. This allows more informed radionuclide selection.
Tables
Summary of the radiologic characteristics for the isotopes studied in Hirsch et al3
Radioisotope T1/2 Decay Mode Decay Summary 32P 14.29 days β− Eavg = 694 keV, Emax = 1710 keV, (Rcsdamax)bone = 4.75 mm 166Ho 26.8 hours β− Eavg = 666 keV, Emax = 1854 keV, (Rcsdamax)bone = 5.20 mm 90Yb 64.1 hours β− Eavg = 934 keV, Emax = 2284 keV, (Rcsdamax)bone = 6.51 mm 125I 59.3 days ε Eavg = 28 keV, Yγ = 159.6% 18F 110 mo β+ Eavg = 633.5 keV, Emax = 249.8 keV, (Rcsdamax)bone = 1.0 mm; produces 511 keV annihilation photons, Yγ = 96.73% 99mTc 6.01 hours IT Eavg = 131 keV, Yγ = 96.5% Note:—32P indicates phosphorus-32; 166Ho, holmium-166; 90Yb, yttrium-90; 125I, iodine 125; 18F, fluorine-18; 99mTc, technetium-Tc99m; ε, low energy photon; T1/2, half-life; IT, mid energy photon; Eavg, average energy; Emax, max energy; (Rcsdamax)bone, continuous-slowing-down-approximation of maximum range in bone; Yγ, gamma photon yield.
